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Introduction: Dissolution is the amount of substance that goes into solution per unit time under
standardised conditions of liquid/solid interface, solvent composition and temperature. Dissolution is
one of the most important tools to predict the in-vivo bioavailability and in some cases to determine
bioequivalence and assure interchangeability.
Aim: To compare the differences in dissolution behaviour of solid dosage forms between innovators
(reference products) and their generic counterparts (tested products).
Methods: Four replicates for each batch of 37 tested medicines was carried out using A PT-DT70
dissolution tester from Pharma Test. A total of 13 branded medicines and 24 generic counterparts were
obtained locally and internationally to detect any differences in their dissolution behaviour. They were
tested according to the British Pharmacopeia, European Pharmacopeia and the US Pharmacopeia with
the rate of dissolution determined by ultra-violet Spectrophotometery.
Results: Most tested medicines complied with the pharmacopoeial speciﬁcations and achieved 85%
dissolution in 60 min. However, some generic medicines showed signiﬁcant differences in dissolution
rate at 60 and 120 min. Many generic medicines showed a slower dissolution rate than their branded
counterparts such as the generic forms of omeprazole 20 mg. Some showed an incomplete dissolution
such as the generic form of nifedipine 10 mg. Other generics showed faster dissolution rate than their
branded counterpart such as the generic forms of meloxicam 15 mg. Moreover, some generics from
different batches of the same manufacturer showed signiﬁcant differences in their dissolution rate such
as the generic forms of meloxicam 7.5 mg. Nevertheless, some generic medicines violated the EMA and
the FDA guidelines for industry when they failed to achieve 85% dissolution at 60 min, such as the
generic form of diclofenac sodium 50 mg.
Conclusion: Most medicines in this study complied with the pharmacopeial limits. However, some
generics dissolved differently than their branded counterparts. This can clearly question the inter-
changeability between the branded and its generic counterpart or even among generics.
& 2011 Elsevier B.V. All rights reserved.1. Introduction
Encouraging generic drugs and substitution from multiple
sources into the healthcare system is aimed at maximising popula-
tion health subject to a budget constraint. This, as a result can
improve the overall healthcare delivery systems [1]. For example, in
the US, generic drugs represent 47% of all prescriptions dispensed in
1999, 61% in 2006 and 69% in 2008 [2]. Approving generic drugs in
the US has resulted in an average savings of 77% of the product costll rights reserved.
gy, Barts and The London,
44 20 7882 3413;
Ameri).within 1 year [3]. Similarly, the UK’s generic substitutions have been
widely successful; they account for 83% [4]. This increase has
occurred because any drug products that are considered bioequiva-
lent must be identical in quality (active ingredient, strength, purity,
content uniformity, disintegration and dissolution rates) [5]. How-
ever, this has been accompanied by a variety of problems of which
the most critical is the widespread distribution of substandard
generics and fake drug products. As a consequence, healthcare
providers and patients are usually concerned when selecting one
drug from among several bioequivalent ones during the treatment
regime [5,6].
In order to maintain a quality control procedure in research
and development, dissolution testing has been employed over the
past 50 years to detect the inﬂuence of critical manufacturing
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(IVIVC) [7]. It can be used to pin point formulations that may
present potential bioequivalence problems. Therefore, it is con-
sidered one of the most important tools to predict the in-vivo
bioavailability and in some cases replacing clinical studies to
determine bioequivalence. Dissolution testing in-vitro is also
considered critical because drug release from the solid dosage
form after oral administration is a prerequisite for drug absorp-
tion and bioavailability [8]. It is a very important test and
considered the rate limiting step in the sequence of steps leading
to absorption of the drug into systemic circulation [9]. Absorption
is the process of transporting the drug substances from the
gastrointestinal lumen into the systemic circulation [10]. It is
the ﬁrst step before the distribution, metabolism and elimination
(ADME) properties of drugs in the human body. An important
feature of drug quality assurance includes the ability to conﬁrm
that the correct manufacturing procedures have been followed for
a given batch, that the product performs effectively throughout its
shelf life and that batch-to-batch reproducibility of the product
meets regulatory requirements [11].
Dissolution is deﬁned as the amount of substance that goes into
solution per unit time under standardised conditions of liquid/solid
interface, solvent composition and temperature [12]. Although
dissolution cannot be used as a predictor of therapeutic efﬁciency;
it can be used as a qualitative and a quantitative tool, which can
provide important information about biological availability of a
drug as well as batch-to-batch consistency [13]. In the cases when
the in-vitro results fail to predict the in-vivo performance of a drug
product, larger clinical studies are needed to assess the product
bioavailability, thus additional cost will be added to the drug
development expenses [11]. Therefore, dissolution is considered
one of the most important quality control tests performed on
pharmaceutical dosage forms and validation of dissolution meth-
ods and is an important part of good manufacturing practice [12].
With modern technology and advancement in research of drug
delivery and more emphasis on in-vivo predictability of therapeutic
effect by means of in-vitro test, dissolution tests have been gaining
more andmore popularity [14]. Whenever a new solid dosage form
is developed or produced, it is necessary to ensure that drug
dissolution occurs in an appropriate manner. The ultimate aim of
performing dissolution tests is to predict the extent release and
absorption of the administered drug in-vivo, i.e. in-vitro–in-vivo
correlation. However, extended release performance obtained in-
vitro does not necessarily mean that the formulation will perform
similarly in-vivo [14].
The pharmacological activity of a drug can be evaluated by
assessing its dissolution behaviour. Therefore, in-vitro–in-vivo
correlation (IVIVC), which is a direct relationship between bioa-
vailability of a drug and its in-vitro dissolution rate is demon-
strated. Drug absorption from solid dosage form following oral
administration depends on the stages disintegration, disaggrega-
tion, drug release from the pharmaceutical form, its dissolution
under physiological conditions and the permeability through the
biological membranes [15]. These considerations indicate that an
in-vitro dissolution test is a very important stage to predict the
drug in-vivo performance. The bioavailability, which describes the
rate and extent of the active drug that is absorbed, may be altered
by any factor that changes the disintegration and dissolution drug
process [15]. For a new compound, dissolution testing is per-
formed mainly to evaluate the stability of formulations, rate of
drug release, monitor product consistency and establish in-vitro–
in-vivo correlations [16]. This type of correlation would match
changes in the in-vitro dissolution rate to meaningful in-vivo
product performance quality. To utilise the dissolution test as a
surrogate for bioequivalence, IVIVC must be predictive of in-vivo
performance of the drug [9].The FDA guidance for industry indicates that for highly soluble
drugs a single point dissolution test speciﬁcation of 85% in 60 min
or less is sufﬁcient as a routine quality control test for batch-to-
batch uniformity [17]. Similarly the EMA guidance which states
that ‘‘In cases where more than 85% of the active substances are
dissolved within 15 min, the similarity of dissolution proﬁles may be
accepted as demonstrated’’ [18]. This test is mainly designed to
obtain correlation with in-vivo performance of the formulation. If
a good correlation is obtained with an in-vitro test, the test may
serve as a routine quality control or may be useful in screening
new drug formulations [8]. Historically, dissolution testing has
been a key tool to measure product performance during the
development stage and to characterise the drug release mechan-
ism. Commercially, dissolution testing is used to conﬁrm product
consistency and to evaluate the quality of the product during its
shelf life and to assess post approval changes and the need of
bioequivalence studies [16].2. Objective
The aim of this study was to compare the differences in
dissolution rate of solid dosage forms between innovators (refer-
ence products) and their generic counterparts (test products).3. Methods
The development of a dissolution procedure involves selecting
the dissolution tester, media, apparatus type (Paddle or basket)
and hydrodynamic (agitation rate) appropriate for the product.
The Low-Head Tablet Dissolution Test Apparatus (model PT-
DT70) equipped with six dissolution vessels [19] from Pharma
Test Company was used to conduct this study. The dissolution
tests were carried out using 37 medicines (tablets and capsules)
containing the same drug substances but different types and/or
amount of excipients. A total of 13 innovator (branded) medicines
and 24 generic counterparts were obtained locally and interna-
tionally to detect any differences in their dissolution behaviour
(Table 1). All the tested tablets and capsules stored according to
conditions described on their labels and were weighed individu-
ally before performing the dissolution test using Sartorius AZ64
Research Analytical Weighing Balance. The average weight of the
obtained tablets and capsules were calculated using Microsoft
Ofﬁce Excel 2007 (Table 3). The temperature was maintained at
3770.5 1C during the dissolution test for 2 h (120 min) [20].
The dissolution test was performed by manually pipeting out
5 ml samples of dissolution medium at 5, 15, 30, 60, 90 and
120 min and transferring to tubes. The medium, apparatus type
and agitation rate for each drug were prepared according to the
British Pharmacopeia (2011) [21], European Pharmacopeia (2007)
[22] and the US Pharmacopeia (USP-30) [23]. The test was carried
out on four replicates for each batch using the paddle method
(apparatus type 2). Deionised water at purity of 18.2 MO cm was
used for the preparation of dissolution media and was obtained
from ultra water system (Model Purelabs). Samples were ﬁltered
appropriately through a 20 mm ﬁlter before measuring the absor-
bance using ultra-violet/visible spectrophotometery (model 6715
UV/Vis. Sectrophotometer, Jenway) (Table 2).
In order to demonstrate whether the method was suitable for
its intended purposes, it was validated through precision (repeat-
ability and reproducibility) parameters based on relative standard
deviation. Validation of dissolution methods was necessary for
the formulation research and development. The precision of an
analytical procedure was determined by repeated analysis (n¼4)
expressed the closeness between a series of measurements
Table 2
In-vitro dissolution procedures for different medicines.
Drug Dissolution medium Volume
(ml)
Agitation rate
(revolutions per minute)
UV Analysis
(wavelength, nm)
Adalat 10 mg 0.1 M hydrochloric acid 900 50 340
Amoxil 500 mg Water 900 75 272
Augmentin 1000 mg Water 900 75 272
Augmentin 375 mg Water 900 75 272
Claritine 10 mg 0.1 M hydrochloric acid 900 50 280
Ciproxin 250 mg 0.1 N hydrochloric acid 900 50 276
Losec 20 mg Phosphate Buffer, pH 7.4 900 75 302
Mobic 7.5 mg Phosphate Buffer, pH 7.5 1000 50 362
Mobic 15 mg Phosphate buffer, pH 7.5 1000 50 362
Ponstan 500 mg 0.05 M Tris buffer 900 100 285
Voltaren 50 mg 0.1 N hydrochloric acid 900 50 276
Xeloda 500 mg Water 900 50 304
Zocor 20 mg 0.01 M sodium dihydrogen orthophosphate containing
0.5% w/v of sodium dodecyl sulphate, pH 7.0
900 50 238
Table 1
Characteristics of the branded medicines (reference products) used in the dissolution study.
Formulation Brand
names
Strength
(mg)
Type (tablet/
capsule)
Indication Batch no. Manufacturer
Nifedipine Adalats 10 Capsule Antihypertensive agent ITA07KZ Bayer Schering Pharma
(Germany)
Amoxicillin Amoxils 500 Capsule Antibiotic to treat bacterial infections 449630 GlaxoSmithKline (UK)
Amoxicillin and
Clavulanate Potassium
Augmentins 375 Tablet Antibiotic to treat bacterial infections 500791 GlaxoSmithKline (UK)
Amoxicillin and
Clavulanate Potassium
Augmentins 1000 Tablet Antibiotic to treat bacterial infections 471504 GlaxoSmithKline (UK)
Loratadine Claritines 10 Tablet H1 histamine antagonist used to treat allergies ORXFA14005 Shering-Plough Labo
N.V. (Belgium)
Ciproﬂoxacin Ciproxins 250 Tablet Antibiotic to treat bacterial infections ITA0924 Bayer Schering Pharma
(UK)
Omeprazole Losecs 20 Capsules Proton Pump Inhibitor to treat peptic ulcer disease MK7422 AstraZeneca (UK)
Meloxicam Mobics 7.5 Tablet Nonsteroidal anti-inﬂammatory to treat arthritis 044155 Boehringer Ingelheim
(UK)
Meloxicam Mobics 15 Tablet Nonsteroidal anti-inﬂammatory to treat arthritis 905341 Boehringer Ingelheim
(Germany))
Mefenamic Acid Ponstans 500 Tablet analgesic and anti-inﬂammatory 15249 Chemidex Pharma Ltd
(UK)
Diclofenac Sodium Voltarens 50 Tablet analgesic and anti-inﬂammatory TO418 Novartis (Italy)
Capecitabine Xelodas 500 Tablet Chemotherapeutic agent to treat metastatic breast
and colorectal cancers
X0115B01 Roche (Mexico)
Simvastatin Zocors 20 Tablet Anticholesteremic agent 305435 MSD (UK)
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sample under the same conditions. Repeatability expresses the
precision under the same operating conditions over a short
interval of time. Reproducibility expresses the precision between
laboratories, in this study standardised procedures from pharma-
copoeias was included [24].4. Results
Dissolution testing involves dissolving the solid dosage form of
a drug compound under controlled conditions, followed by
collection and analysis of the sample to determine the percentage
of drug dissolved at certain time point. The volume of the
dissolution medium was kept constant and corrected mathema-
tically using Microsoft Ofﬁce Excel 2007 and Minitab 16 (Minitab
Inc, Pennsylvania, PA, USA). The results of this study were
expressed as % (95% Conﬁdence Intervals (CI)). Variations were
evaluated using the one-way analysis of variance (ANOVA) and
Pr0.05 was considered statistically signiﬁcant. Dissolution pro-
ﬁle compares the percentage of a drug substances dissolved
relating to time and represents an alternative to assessment ofsolid forms before clinical tests [15]. Tables 3 and 4 show the
percentages of the dissolution of all drugs at 60 and 120 min,
respectively.5. The dissolution rate of generic medicines compared to their
branded counterpart at 60 min, Table 3
When comparing the dissolution rates between the branded
medicines and their generic counterparts at 60 min, 21% (5/24) of
the generic medicines had shown statistically signiﬁcant differ-
ences than their branded counterpart. On one hand, some
generics showed different and incomplete dissolution rates than
their branded counterparts such as the generic form of capecita-
bine 500 mg (P¼0.001). Another example is meloxicam 15 mg
where its generic A showed a slower dissolution rate than its
branded counterpart (P¼0.001), Fig. 1. In addition, the generic
form (Generic A1) of meloxicam 7.5 mg had shown slower
dissolution rate than its branded counterpart (P¼0.032). Another
example is that the dissolution rate of the generic form (Generic
A) of omeprazole 20 mg had shown a slightly slower dissolution
rate than its branded counterpart (P¼0.054). Moreover, some
Table 4
Shows the percentages of the dissolution rate of the generic medicines (test
products) compared to their branded counterparts which was taken as the
reference at 100% of the expected dissolution rate at 120 min.
Drug name % of drug dissolved
at 120 min
95% Conﬁdence interval P value
Adalats 100 0.003
Generic A 86 (80–93)
Amoxils 100 0.005
Generic A 105 (98–113)
Generic A1 104 (97–112)
Generic B 113 (105–121)
Augmentins 375 mg 100 0.127
Generic A 87 (71–106)
Augmentins 1000 mg 100 0.019
Generic A 94 (90–99)
Claritines 100 0.132
Generic A 103 (99–107)
Generic B 101 (97–105)
Ciproxins 100 0.905
Generic A 100 (95–105)
Generic B 101 (96–106)
Losecs 100 0.001
Generic A 113 (105–123)
Generic B 124 (115–135)
Mobics 7.5 mg 100 0.204
Generic A 101 (91–113)
Generic A1 94 (84–105)
Mobics 15 mg 100 0.043
Generic A 98 (89–107)
Generic A1 104 (95–114)
Generic B 109 (99–119)
Ponstans 100 0.047
Generic A 92 (84–101)
Generic B 90 (82–98)
Voltarens 100 0.312
Generic A 101 (44–231)
Generic B 64 (28–147)
Xelodas 500 mg 100 0.008
Generic A 90 (84–96)
Zocors 100 0.733
Generic A 106 (77–145)
Generic B 96 (70–132)
Brand: The innovator product. Generic A: counterpart of the branded medicine,
Generic A1: same manufacturer with different batch number of generic A and
Generic B: second generic counterpart of the same branded medicine.
Table 3
Shows the percentages of the dissolution rate of the generic medicines (test
products) compared to their branded counterparts which was taken as the
reference at 100% of the expected dissolution rate at 60 min.
Drug name Average
weight (g)
% of drug dissolved
at 60 min
95% Conﬁdence
interval
P value
Adalats 0.59875 100 0.001
Generic A 0.61532 87 (82–92)
Amoxils 0.691810 100 0.263
Generic A 0.68846 99 (91–107)
Generic A1 0.698708 104 (96–113)
Generic B 0.698363 104 (96–113)
Augmentins
375 mg
0.67019 100 0.132
Generic A 0.66545 83 (64–108)
Augmentins
1000 mg
1.48098 100 0.145
Generic A 1.44494 95 (88–102)
Claritines 0.10000 100 0.449
Generic A 0.09970 101 (98–104)
Generic B 0.11713 99 (96–102)
Ciproxins 0.38277 100 0.613
Generic A 0.39973 101 (93–109)
Generic B 0.40445 103 (95–111)
Losecs 0.29163 100 0.054
Generic A 0.29875 94 (87–101)
Generic B 0.28517 101 (94–109)
Mobics
7.5 mg
0.18218 100 0.032
Generic A 0.11150 101 (90–113)
Generic A1 0.11150 89 (79–100)
Mobics 15 mg 0.18217 100 0.001
Generic A 0.182165 91 (83–100)
Generic A1 0.22036 100 (91–110)
Generic B 0.22170 114 (104–126)
Ponstans 0.69577 100 0.063
Generic A 0.74245 92 (82–104)
Generic B 0.82695 97 (86–109)
Voltarens 0.21431 100 0.200
Generic A 0.20725 103 (60–176)
Generic B 0.22830 72 (42–122)
Xelodas
500 mg
0.63751 100 0.003
Generic A 0.98755 86 (80–93)
Zocors 0.20649 100 0.738
Generic A 0.20322 98 (66–146)
Generic B 0.20330 90 (60–133)
Brand: The innovator product. Generic A: counterpart of the branded medicine,
Generic A1: same manufacturer with different batch number of the generic A and
Generic B: second generic counterpart of the same branded medicine.
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form of nifedipine 10 mg, Fig. 3.
On the other hand, a number of generics showed that they can
dissolve faster than their branded counterparts. For example, the
generic form (Generic B) of meloxicam 15mg showed faster
dissolution rate than its branded counterpart (P¼0.001), Fig. 1.
Moreover, other generics showed batch to batch variation during
the dissolution test. This is clearly shown, for example, in generic A
and generic A1 of meloxicam 15mg and meloxicam 7.5 mg, Table 3.
Nevertheless, some generic medicines failed to follow the EMA and
the FDA role of 85% dissolution in 60 min. For instance, 76% of
generic B in diclofenac sodium 50 mg had only dissolved at 60 min
compared to 100% dissolution of its branded counterpart, Fig. 2.6. The dissolution rate of generic medicines compared to their
branded counterpart at 120 min, Table 4
When comparing the branded medicines with their generic
counterparts at 120 min, more than half (54%, 13/24) of the tested
generic medicines were found signiﬁcantly different (pr0.05)than their branded counterpart. Some generic medicines showed
slower and incomplete dissolution rates than their branded
counterpart. For example, the generic form of nifedipine 10 mg
(Fig. 3) and capecitabine 500 mg showed much slower dissolution
rate than their branded counterpart (P¼0.003, 0.008, respec-
tively). The generic form of amoxicillin and clavulanate potassium
1000 mg had also shown a slower dissolution rate than its
branded counterpart (P¼0.019). In addition, the generic form
(Generic A) of meloxicam 15 mg has shown a slower dissolution
rate than its branded counterpart (P¼0.043). In mefenamic acid
500 mg, the generic A and B also showed a signiﬁcantly lower
dissolution rate than their branded counterpart (P¼0.047).
Other generics showed that they can dissolve faster than their
branded counterpart. For example, all tested generic forms
(Generic A, A1 and B) of amoxicillin 500 mg dissolved faster than
their branded counterpart (P¼0.005), Fig. 4. The generic forms
(Generic A and B) of omeprazole 20 mg also dissolved faster than
their branded counterpart (P¼0.001). Likely, the generic forms
(Generic A1 and B) of meloxicam 15 mg had shown faster
dissolution rates than their branded counterpart (P¼0.043),
Fig. 1. Nevertheless, some generics showed batch to batch varia-
tion in their dissolution rate; for example, the generic forms
(generic A and A1) of meloxicam 15 mg (P¼0.043).
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Fig. 1. The differences in dissolution rate between the branded Mobics 15 mg and its generic counterparts (Generic A: counterpart of the branded medicine, Generic A1:
same manufacturer with different batch number of generic A and Generic B: second generic counterpart of the same branded medicine).
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Fig. 2. The differences in dissolution rate between the branded Voltarens 50 mg and its generic counterparts (Generic A: counterpart of the branded medicine and Generic
B: second generic counterpart of the same branded medicine).
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The results of this study are found compatible with others in
Refs. [5,25,26].
The dissolution rate proﬁle revealed that many of the branded
and generic medicines tested in this study complied with the
British Pharmacopeia (2011) [21], European Pharmacopeia (2007)
[22] and the US Pharmacopeia (2010) [23]. Most drugs in this
study achieved 85% dissolution at 60 min or less. This is compa-
tible with the EMA and the FDA guidance for industry indicating
that for highly soluble drugs a single point dissolution test
speciﬁcation of 85% in 60 min or less is sufﬁcient as a routine
quality control test for batch-to-batch uniformity [17]. This can
reﬂect that the in-vivo bioavailability of these drugs would besimilar to in-vitro since dissolution testing is commonly used to
predict in-vivo behaviour of the oral dosage formulation.
Many generic medicines in this study showed signiﬁcant
differences from their branded counterparts during the dissolu-
tion tests. Some generics showed incomplete dissolution and
others showed that they dissolve slower or faster than their
branded counterparts. Nevertheless, signiﬁcant differences in
dissolution rate were also shown in batch to batch comparison.
Some generics from the same manufacturer with different
batches of the same drug showed signiﬁcant differences. This
illustrates that substitution among generics themselves can be
risky. Unfortunately, some other generic medicines in this dis-
solution test failed to achieve the 85% dissolution at 60 min. These
differences in dissolution rate between the branded and their
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Fig. 3. The differences in dissolution rate between the branded Adalats 10 mg and its generic counterparts (Generic A: counterpart of the branded medicine).
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Fig. 4. The differences in dissolution rate between the branded Amoxils 500 mg and its generic counterparts (Generic A: counterpart of the branded medicine, Generic A1:
same manufacturer with different batch number of generic A and Generic B: second generic counterpart of the same branded medicine).
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side-effects proﬁles [27].
There are many potential factors that can explain the differ-
ences between the branded and their generic counterparts. Those
include the manufacturer, apparatus type, surface area of a drug,
surfactants, storage, dosage form and the level and type of
excipients. Manufacturer of the drug can play a major part in its
dissolution proﬁle. In the literature, it is reported that there are
variable clinical responses to the same dosage form of a drug
product supplied by different manufacturers. For example, a
study compared 19 different generic formulations of simvastatin
tablets and capsules obtained from international manufacturers
to the US innovator product regarding pharmaceutical quality. It
revealed that manufacturing standards for the international
generics were not equivalent in quality aspects with the US
innovator drug, a signiﬁcant variability was also found amongforeign-made tablets themselves [28]. Similarly, another study
compared the dissolution behaviour of six diclofenac sodium
prolonged release tablets of different brands obtained from the
national market. It reported that the release characteristics vary
considerably among different manufacturers and that even iden-
tical formulations showed rather dissimilar release proﬁles.
Therefore the interchangeability of these drugs is questioned [25].
The apparatus type (paddle vs. basket) can also affect the
dissolution test and it depends largely on the physiochemical
properties of the dosage form [29]. Another possible reason for
the difference in dissolution rate is the difference in particle or
surface area of the drug particles [30]. Solid dosage form may or
may not disintegrate when interacting with gastrointestinal ﬂuid
after oral administration following their design. Since disintegra-
tion determines to a large extent the area of contact between the
solid and liquid, it usually plays a vital role in the dissolution
M.N. Al Ameri et al. / Results in Pharma Sciences 2 (2012) 1–8 7process. However, it should be noted that there is no automatic
correlation between disintegration and dissolution, especially
with poorly soluble drugs [29].
The use of surfactant such as sodium lauryl sulphate, which is
essential for poorly soluble drugs such as simvastatin can also
affect the dissolution rate [31]. In cases where a higher concentra-
tion of surfactant is used can lead to faster dissolution and any
correlation with in-vivo performance can be lost, therefore a low
surfactant is a modiﬁer of choice [31]. The storage of a drug can
also affect their dissolution proﬁle. For example, a study evaluated
the differences between the branded and their generic counterpart
of dicloﬁnac sodium on the dissolution rate after storing under
40 1C, 75% relative humidity. It revealed that the dissolution rate of
the generic form of dicloﬁnac sodium was reduced signiﬁcantly
during storage time compared to its branded counterpart [32].
Another Egyptian study detected wide variations in in-vitro per-
formance of omeprazol capsules. It revealed that the branded
medicine was found more resistant to changes caused by the
packaging material than its generic counterparts [33].
Differences in dissolution rates between the branded and their
generic counterpart drugs can also be related to the composition
of excipients. This can mainly inﬂuence the side-effects proﬁles of
the generic drugs. Results in this study, like others in the
literature, suggests that when performing generic substitution,
switching among generics and/or switching from one form to
another for the same medicine, patient monitoring should be
essential especially for the side effects [34]. Excipients are sub-
stances other than the pharmacologically active ingredients,
which include binders, ﬁllers, disintegrates, lubricants, sweet-
eners, preservative, ﬂavours, colours, printing inks, etc. [35,36].
Although excipients are considered the inactive ingredients
that do not have therapeutic effect, some studies have revealed
that excipients can cause various side effects [36]. In many cases
the performance of a drug can greatly depend on the quality of
excipients used in manufacturing and on the quality of the
process [25]. In the literature, for example, it was reported that
the excipients in one of the generic form of simvastatin caused
the rapid release of the drug during the ﬁrst 5 min of the
dissolution test [37]. Moreover, a study showed that different
formulations of digoxin (cardiac glycosides, narrow therapeutic
index drug) yielded tremendous differences in the dissolution
proﬁles. The study indicates that either batch-to-batch or
amongst brands bio-in-equivalence originates from differences
in dissolution rates [38]. It is well known that digoxin is a narrow
therapeutic index medicine, which means that small changes in
dissolution rates can make problems because of too many side
effects or too little effectiveness [38].8. Conclusion
This study indicates that dissolution test is well established,
reproducible, reliable and valuable tool for characterising a drug
product at different stages in its lifecycle. The results clearly raise
a question about the interchangeability between branded medi-
cines and their generic counterparts and among generics them-
selves. This strongly suggests the need to assess patients after
performing generic substitution. In addition, the role and regula-
tion surrounding drug substitution should be strengthening to
maintain the quality of care. Likewise, Danish Medicines Agency
has terminated the generic substitution for oral medicines con-
taining ciclosporine or tacrolimus [39]. Healthcare providers
should take into account that deﬁnitely generics save money,
but recognise that in some cases it may be advisable to monitor
patients upon generic substitution of some classes of drugs, such
as narrow therapeutic index or transplant drugs.9. Main limitations of the study
Dissolution test is used to forecast the in-vivo behaviour of a
drug. However, deﬁnite conclusions about the bioavailability and
bioequivalence of these products should be conducted in-vivo
studies. It is critical that the in-vitro test should mimic the in-vivo
conditions as closely as possible. Given the nature of the human
GI tract and various factors that affect its activity, the general-
isation of dissolution conditions and results of this study is not
recommended. In-vivo–in-vitro comparison studies are required
to conﬁrm ﬁndings in this study.Competing interests
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